Abstract: The present invention concerns esters of R-enantiomers of a non-steroidal anti-inflammatory drug, which is substantially free from the S-enantiomer. The compounds of the invention may be used in treating a disease or illness in a mammal. To this end, a composition comprising a compound mentioned above, or a pharmaceutically acceptable salt thereof where salt formation occurs, is administered to the mammal in an amount sufficient to elicit a chemopreventative effect or a chemoprotective effect or a therapeutic effect or a prophylactic effect.

Abstract: A process for the preparation of 2-bromomethyl-6-methyl-benzoic acid (I) and derivatives thereof by selective bromination of 2,6-dimethylbenzoic acid (II) with sodium bromate and hydrobromic acid in the presence of light.

Abstract: The present invention relates to non-steroidal progestins of the general formula (I) 1

Abstract: Chemically amplified resist is produced on the basis of vinyl polymer having 3-oxo-4-oxabicyclo[3.2.

Abstract: This invention provides O-&agr;-acyloxyalkyl ethers of the venlafaxine metabolite 4-[2-(Dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenol, represented by Formula (I): 1

Abstract: The instant invention discloses a process for the preparation of compounds of formula I wherein the general symbols are as defined in claim 1, which process comprises hydrolyzing a compound of formula V wherein the general symbols are as defined in claim 1, in an aqueous solvent in the presence of an acid. The compounds of the formula V are new and useful as stabilizers for protecting organic materials, in particular polymers and lubricants, against oxidative, thermal or light-induced degradation.

Abstract: A process for the preparation of aniline compounds of formula 1

Abstract: Synthetic polymers which possess outstanding stability to oxidative, thermal or light-induced degradation comprise as stabilizer at least a compound of the formula I 1

Abstract: Chemically amplified resist is produced on the basis of vinyl polymer having 3-oxo-4-oxabicyclo [3.2.

Abstract: Process for the preparation of compounds of formula I 1

Abstract: The invention provides a process for preparing an enantiomerically enriched cis-6,6-dimethyl-3-oxa-bicyclo[3.1.0]hexan-2-one by reacting a sulphonic ester of &bgr;,&bgr;-dimethyl-&ggr;-(hydroxymethyl)-&ggr;-butyrolactone with a compound of formula M(C1-6 alkoxide)y.

Abstract: A process for the preparation of cis-6,6-dimethyl-3-oxa-bicyclo[3.1.0]hexan-2-one which comprises either: 1) reacting a sulphonic ester of &bgr;,&bgr;-dimethyl-&ggr;-(hydroxymethyl)-&ggr;-butyrolactone with a compound of formula M(C1-6 alkoxide)y, in a suitable solvent; or 2) reacting a C1-4 alkyl ester of 4,5-epoxy-3,3-dimethylpentanoic acid with M(C1-6 alkoxide)y, in a suitable solvent; wherein M is a suitable cation and y fulfills valency requirements.

Abstract: 3,6-Dimethyl-2(3H)-benzofuranone is a new, valuable flavor material. A process for its industrial-scale preparation was developed.

Abstract: The present invention relates to novel substituted bicyclic lactones, to processes for their preparation and to their use for the prevention and/or treatment of disorders caused by hyper- or hypofunction of the glutamatergic system, in particular of cerebral ischaemias, cranial cerebral trauma, states of pain or CNS-mediated spasms.

Abstract: A series of activated iodo-benzamide derivatives are described as antineoplastic and antiviral drug compounds. The compounds generally possess a chelating group, a thiol trapping group and an activating group. The presumptive mechanism of action in preventing cancer cell and virus replication is through inhibition of the binding of transcription factors to zinc finger binding domains. The compounds are effective in inhibiting growth of a variety of human and animal tumor and leukemia cell lines at low concentrations.

Abstract: The present invention relates to a process for coloration of a high molecular weight material by admixing said high molecular weight organic or inorganic material, preferably high molecular weight organic material, prior to processing with at least one compound of the formula: where A1 and A2 are independently unsubstituted, monosubstituted, disubstituted, trisubstituted or tetrasubstituted o-C6-C18arylene. The invention further relates to compositions of matter comprising isoxindigo compounds and high molecular weight organic material. The invention also relates to processes for preparing the compound of the formula (I) and also to novel isoxindigo compounds which can be symmetrical or asymmetrical or else have a bisisoxindigo structure.

Abstract: The present invention provides novel haloenol lactones that are effective as active site inhibitors of cholesterol esterase. By inhibiting cholesterol esterase the inhibitors of the present invention provide a new approach to the treatment of hypercholesterolemia through limiting the bioavailability of dietary cholesterol.

Abstract: The compounds 3-(2,2-dichloro-3,3,3-trifluoro-1-hydroxypropyl)-2,2-dimethyl-(1R,cis)-cyc lopropane carboxylic acid, cis-3-(2,2-dichloro-3,3,3-trifluoro-1-hydroxypropyl)-2,2-dimethyl-cyclopro pane carboxylic acid and (1R,5S)-4-(1,1-dichloro-2,2,2-trifluoroethyl)-6,6-dimethyl-3-oxabicyclo[3. 1.0]hexan-2-one occur as intermediates in a process for the preparation of insecticidally active cyclopropane carboxylate esters, said process starting from 6,6-dimethyl-4-hydroxy-3-oxabicyclo[3.1.0]hexan-2-one (Biocartol) which is reacted with the compound CF.sub.3 --CC1X.sub.2 (X=halogen) in the presence of zinc.

Abstract: Compounds of the formula ##STR1## wherein the variables are defined as in the specification, are capable of lowering introaocular pressure in the eye of a mammal.

Abstract: Benzodifurantriones of Formula (1): ##STR1## in which W is unsubstituted or substituted aryl, a process for their preparation via dioxo intermediates and processes for their conversion into benzodifuranone dyes and compounds of Formula (7): ##STR2## are provided wherein R.sup.3 is --H, --COR.sup.2, --SO.sub.2 R.sup.2 -- which R.sup.2 is alkyl, cycloalkyl, aryl or aralkyl and R.sup.4 is --COOR.sup.2, --CONRR.sup.1 in which R and R.sup.1 each independently is --H, alkyl, cycloalkyl, aryl or aralkyl; --COOH or the alkali metal, alkaline earth metal or ammonium salts thereof; or --COX.sup.2 -- which X.sup.2 is halo.

Abstract: Compounds of the formula ##STR1## where W is (CH.sub.2).sub.n where n is 1 or 2, or n is 0 and W represents lower alkyl groups attached to each oxygen;m is an integer between 1 and 8;R.sub.1 is COOH or a pharmaceutically acceptable salt thereof, COOR.sub.4, CONR.sub.5 R.sub.6, CONR.sub.5 SO.sub.2 R.sub.7, CH.sub.2 OH, CH.sub.2 OR.sub.7, CH.sub.2 O--COR.sub.7, CH.sub.2 O--CONR.sub.5,R.sub.7, CH.sub.2 OCOOR.sub.7, CH.sub.2 NH.sub.2, CH.sub.2 NR.sub.5 R.sub.6, CH.sub.2 NR.sub.5 COR.sub.7, CHO, CH(OR.sub.8).sub.2, CHOR.sub.9 O, --COR.sub.10, CR.sub.10 (OR.sub.8).sub.2, or CR.sub.10 OR.sub.9 O, where R.sub.4 is an alkyl group of 1 to 10 carbons, or a cycloalkyl group of 5 to 10 carbons, or R.sub.4 is phenyl or lower alkylphenyl, R.sub.5 and R.sub.6 independently are hydrogen, an alkyl group of 1 to 10 carbons, or a cycloalkyl group of 5 to 10 carbons, or phenyl or lower alkylphenyl, R.sub.7 is alkyl of 1 to 10 carbons, phenyl or lower alkylphenyl, R.sub.8 is lower alkyl, and R.sub.

Abstract: A cyclopropane derivative represented by formula (I): ##STR1## wherein B represents a group of a purine derivative. In addition another aspect of the invention provides (3-oxa-2-oxobicyclo[3,1,0]hexan-1-yl)methanol and a method of preparing a cyclopropane derivative of formula (I) from this compound by replacing the hydroxyl group of the compound with a leaving group followed by reaction with a purine derivative.

Abstract: The magnesium complexes of cyclic hydrocarbons containing conjugated dienes, such as 1,2-dimethylenecycloalkanes, and 1,3-butadienes, are readily prepared in high yields using highly reactive magnesium. Reactions of these (2-butene-1,4 diyl)magnesium reagents with electrophiles such as dibromoalkanes, alkylditosylates, alkylditriflates, bromoalkylnitriles, esters, or amides serve as a convenient method for synthesizing carbocyclic systems. Significantly, carbocycles prepared by this method contain functional groups such as the exocyclic double bond or a keto group in one of the rings which could be used for further elaboration of these molecules. Furthermore, fused bicyclic systems containing a substituted five-membered ring can be conveniently prepared at high temperatures by the reactions of (2-butene-1,4-diyl)magnesium complexes with carboxylic esters or acid halides whereas low temperatures lead to regioselective synthesis of .beta.,.gamma.-unsaturated ketones. Additionally, .gamma.

Abstract: Compounds of the formula (1) ##STR1## in which R.sub.2, R.sub.3, R.sub.4 and R.sub.5 independently of one another, are hydrogen, C.sub.1 -C.sub.25 alkyl, C.sub.7 -C.sub.9 phenylalkyl, unsubstituted or C.sub.1 -C.sub.4 alkyl-substituted phenyl, unsubstituted or C.sub.1 -C.sub.4 alkyl-substituted C.sub.5 -C.sub.8 cycloalkyl; C.sub.1 -C.sub.18 alkoxy, hydroxyl, C.sub.1 -C.sub.25 alkanoyloxy, C.sub.3 -C.sub.25 alkenoyloxy, C.sub.3 -C.sub.25 alkanoyloxy which is interrupted by oxygen, sulfur or >N--R.sub.16 ; C.sub.6 -C.sub.9 cycloalkylcarbonyloxy, benzoyloxy or C.sub.1 -C.sub.12 alkyl-substituted benzoyloxy, where R.sub.16 is hydrogen or C.sub.1 -C.sub.8 alkyl, or, furthermore, the radicals R.sub.2 and R.sub.3 or the radicals R.sub.4 and R.sub.5 together with the carbon atoms to which they are bound form a phenyl ring, R.sub.4 is additionally --(CH.sub.2).sub.n --COR.sub.11, in which n is 0, 1 or 2, R.sub.11 is hydroxyl, ##STR2## R.sub.14 and R.sub.15, independently of one another, are hydrogen or C.sub.1 -C.

Abstract: The furanones of formula ##STR1## wherein symbols R.sup.1 and R.sup.2, taken separately, are identical and represent each a methyl radical, or are different and represent each a hydrogen atom or a methyl radical, or, taken together, represent a methylene radical, are useful as perfuming ingredients for the preparation of perfuming compositions and perfumed articles, to which they impart odors of the coumarinic and balsamic type.

Abstract: The present invention is concerned with antiretroviral (e.g. anti HIV-1) compounds having the formula ##STR1## Pharmaceutical compositions containing said compounds of formula (I-a) or (I-b), and processes of preparing said compounds and compositions.

Abstract: 3- or 4-mono-, 1,3- or 1,4- or even 3,4-disubstituted derivatives of quinic acid are produced by reaction of a hydroxycinnamic acid derivative, of which the phenol group(s) is/are protected with a quinic acid derivative, to form an ester and the different reactivities of the OH functions in the 3 and 4 positions are used to carry out the esterification selectively under low temperature conditions, after which the protective groups are cleaved under controlled acidity and temperature conditions. These conditions avoid any degradation or isomerization. The process enables new quinides to be obtained in high yields.

Abstract: 1-, 5-O-mono- and 3,4-0-bis-substituted derivatives of quinic acid are prepared by reacting a derivative of a hydroxycinnamic acid of which the hydroxyl group(s) is/are protected with a quinic acid derivative to form an ester and the protective groups are then cleaved under controlled conditions of acidity and temperature. These conditions provide for regiospecificity of the esterification and enable any degradation of isomerization to be avoided. The process gives new quinides in high yields.

Abstract: A ferroelectric liquid crystal composition including: at least one optically active compound of the formula (I): ##STR1## where R.sup.1 and R.sup.2 are, the same or different, a straight or branched chain alkyl group having 1 to 15 carbon atoms, k represents an integer of 0 or 1, and * represents an asymmetric carbon atom; andat least one compound selected from the group consisting of: compounds of the formula (II): ##STR2## where R.sup.3 and R.sup.4 are a straight or branched chain alkyl or alkoxy group having 1-15 carbon atoms, ##STR3## and ##STR4## each represents ##STR5## X represents --O--, --CO-- or a single bond, m and n are independently an integer of 0 or 1; compounds of the formula (III): ##STR6## where R.sup.5 and R.sup.6 are, the same or different, a straight or branched chain alkyl or alkoxy group having 1-15 carbon atoms, and p is an integer of 0 or 1;said ferroelectric liquid crystal composition exhibiting at least nematic phase, smectic A phase and smectic C phase.

Abstract: A process for preparation of a compound of the formula ##STR1##

Abstract: The primary hydroxy group of Corey lactone diols is optically selectively acylated to obtain the desired optically active ester and/or diol. The mixture of Corey lactone diols of formulae (Ia) and (Ib): ##STR1## is reacted with an acylating agent optically selectively in the presence of an enzyme and/or a microorganism thereby to acylate, isolate and purify the primary alcohol.

Abstract: A chiral catalyst is disclosed together with methods of using it for enantioselective syntheses. The chiral catalyst includes a nucleus with two metal atoms that has four bridging ligands oriented radially to the axis of the nucleus. Each of these ligands includes two complexing atoms each complexed to one of the metal atoms. At least one of the bridging ligands includes a chiral center which is bonded to one of the complexing atoms. Preferably, all four of the bridging ligands include a chiral center bonded to one of the complexing atoms. The catalyst of the invention has been found to be useful in catalyzing carbenoid transformation reactions such as cyclopropanation.

Abstract: Novel substituted lactones of amino acids in all their possible stereoisomeric forms or mixtures thereof of the formula ##STR1## wherein A is a hydrocarbon chain of 1 to 10 chain members containing one or more heteroatoms and one or more unsaturations and the chain members being a mono- or polycyclic system or comprises a system of spiro or endo type and may contain one or more chiral atoms or the lactone copula can present a supplementary chirality due to the asymetric spatial configuration of the molecule make up and R is selected from the group consisting of ##STR2## wherein Z is the organic remainder of an amino acid of the formula ##STR3## Y is derived from a primary, secondary or tertiary alcohol of the formula Y-OH and B is the remainder of a heterocycle amino acid of 3 to 6 carbon atoms of the formula ##STR4## and their preparation and their use for the resolution of amino acids.

Abstract: A method of preparing 1-phenyl-1-diethylaminocarbonyl-2-phthalimidomethyl-cyclopropane-Z and key intermediates therefor are disclosed.This method is characterized by the following successive steps:opening of the 1-phenyl-2-oxo-3-oxa-bicyclo(3:1:0)-hexane by diethylamine or a tertiary amine with the aid of a Lewis acid/amine complex:the 1-phenyl-1-diethylaminocarbonyl-2-hydroxymethyl-cyclopropane-Z thus obtained is converted into a 2-chlorinated derivative by the action of a chlorination reagent such as thionyl chloride; andthe 1-phenyl-1-diethylaminocarbonyl-2-chloromethylcyclopropane-Z is reacted with a phthalimide salt in an organic solvent to produce the 1-phenyl-1-diethylaminocarbonyl-2-phthaliumidomethyl-cyclopropane-Z.

Abstract: A process for the production of esters or lactones, comprising reacting in the presence of a catalyst and under hydrogenation conditions hydrogen and an acyclic or cyclic carboxylic anhydride to produce the corresponding ester or lactone, wherein the catalyst is a supported catalyst comprising:(a) a group VIII metal, Re and Fe;(b) a group VIII metal on TiO.sub.2 ;(c) Ru and at least one of Re, Ag or Cu; or(d) Pd and Fe.Preferably, the anhydride has the formula ##STR1## and is reacted to form an ester of the formula ##STR2## or a lactone of the formula ##STR3## wherein R and R.sup.1 independently are lower alkyl or cycloalkyl; R.sup.2, R.sup.3, R.sup.4, R.sup.5 independently are hydrogen, lower alkyl, cycloalkyl or aryl; and wherein R.sup.3 and R.sup.4 taken together may form a saturated or unsaturated ring, or an aromatic ring. The more preferred starting material is phthalic anhydride.

Abstract: A process is described for the synthesis of hydroxy lactone 3, being 1R, 2R, 5R-2-hydroxy-6-oxo-7-oxabicyclo[3.2.1]-octane, in optically pure form, which is useful as an intermediate in the synthesis of the C.sub.20 -C.sub.34 chain of the macrolide structure for the immunosuppressant FK-506. This compound is also useful as a precursor for producing an ultraviolet radiation absorber.

Abstract: A compound of the formula ##STR1## in its d, 1 or d1 form and mixtures thereof and their preparation and their use in the synthesis of pyrethrinoids.

Abstract: 13-oxabicyclo[10.3.0]pentadecane, a valuable ambergris fragrance, is prepared by reacting cyclododecanone with cyanoacetic acid in the presence of a Knoevenagel catalyst to form cyclododecenylacetonitrile, the nitrile is hydrolyzed to cyclododecenylacetic acid, and the acid is cyclized to the lactone, and the lactone is reduced to the corresponding diol which is cyclized to 13-oxabicyclo[10.3.0]pentadecane.

Abstract: Hydroxy aryl carboxylic acids are formed by reacting a hydroxy aryl compound, such as phenol, with a ketone, such as acetone and carbon monoxide in the presence of a strong acid. The preferred embodiment is the one step formation of 2-methyl-2-(p-hydroxyphenyl) propionic acid from phenol, acetone and carbon monoxide in the presence of hydrofluoric acid. When this reaction is conducted in the presence of methanol the corresponding methyl ester is formed.

Abstract: A method for making a bicyclic lactone comprising heating under aqueous acidic conditions a beta, gamma unsaturated cyclic nitrile and an aldehyde, for a length of time sufficient to convert at least a portion of the reactants to a bicyclic lactone of the formula ##STR1## wherein R.sub.3 is --H; R.sub.4, R.sub.5, and R.sub.6 are independently selected from the group consisting of --H, --CH.sub.3 ; R.sub.2 is selected from the group consisting of --H, --CH.sub.3, and --CH.sub.3, and --C.sub.2 H.sub.5 ; R.sub.8 is --H or --CH.sub.3 ; m is an integer from 1 to 5; o is 0, 1, 2, or 3; and p is 0, 1, or 2; provided that the sum of m+o+p is an integer from 3 to 5; either R.sub.3 or R.sub.8 together with R.sub.7 represents a carbon-carbon bond. The method uses commercially available and relatively inexpensive raw materials as reactants.

Abstract: An improved process for the preparation of compounds of the (1R,4R,5S) or (1S,4S,5R) configuration of the formula ##STR1## wherein Y is selected from the group consisting of hydrogen and the organic residue Z of a chiral alcohol of the formula ZOH is disclosed.

Abstract: 1-Oxo-1,3,4,7-tetrahydrobenzofuranes of the formula ##STR1## in which X is O or S,R is optionally substituted phenyl or heteroaryl,R.sup.1 is OH, monoalkylamino or dialkylamino, andR.sup.2 is an acyl or esterified carboxy radical,or pharmacologically acceptable salts thereof, which are active in circulation, e.g. they increase myocardial contractility, increase the flow of Ca.sup.2+ into the cell, increase blood pressure, reduce blood sugar, reduce swelling of mucous membranes and affect the salt and/or fluid balance.

Abstract: Novel ethers of organic compounds containing chiral atoms of the formula ##STR1## wherein A is a hydrocarbonated chain of 1 to 10 groups, the said chain containing one or more heteroatoms, one or more unsaturations, the assembly of the groups constituting the chain may represent a mono- or polycyclic system, including a system of the spiro or endo type, the chain A can contain one or more chiral atoms or the lactone moiety can present a chirality due to the dissymetric spatial configuration of the whole of the molecule and Z is selected from the group consisting of primary, secondary or tertiary alcohol moiety containing at least an asymetric carbon atom, a phenol moiety substituted comprising at least one asymetric carbon atom and an substituted alcohol or phenol moiety with a chirality due to the dissymetric spatial configuration of the whole of the molecule, with the proviso Z is not (R) or (S) .alpha.

Abstract: A process for preparing an optically active 2-substituted or unsubstituted-4-hydroxy-2-cyclopentenone of the formula: ##STR1## wherein R is a hydrogen atom, an allyl group or a propargyl group, which comprises reacting the corresponding 2-substituted or unsubstituted-4-hydroxy-2-cyclopentenone of the formula: ##STR2## wherein R is defined above with a lactone chosen from (1R,5S)-6,6-dimethyl-4-hydroxy-3-oxabicyc lo[3.1.0]hexan-2-one or (1S,5R)-6,6-dimethyl-4-hydroxy-3-oxabicyclo[3.1.0]hexan-2-one in a molar ratio of 1.5 - 2:1 in the presence of p-toluenesulfonic acid or benzenesulfonic acid in the coexistence of an organic solvent under elimination of water as an azeotropic mixture with the organic solvent to obtain a reaction mixture comprising (1R,5S)-6,6-dimethyl-3-oxa-4(R)-[1(R)-4-oxo-2-substituted or unsubstituted-2-cyclopentenyloxy]bicyclo[3.1.0]hexan-2-one or (1S,5R)-6,6-dimethyl-3-oxa-4(S)-[1(S)-4-oxo-2-substituted or unsubstituted-2-cyclopentenyloxy]bicyclo[3.1.

Abstract: An optically active hydroxyiodolactone of the formula ##STR1## wherein the stereochemistry of the 3a-, 5- and 7a-positions is either (3aR,5S,7aS) or 3aS,5S,7aR). The compound is useful as an intermediate for the production of a large amount of one component of the queen recognizing pheromone of red imported fire ant with a high optical purity.

Abstract: 1-Oxo-1,3,4,7-tetrahydrobenzofuranes of the formula ##STR1## in which X is O or S,R is optionally substituted phenyl or heteroaryl,R.sup.1 is OH, monoalkylamino or dialkylamino, andR.sup.2 is an acyl or esterified carboxy radical, or pharmacologically acceptable salts thereof, which are active in circulation, e.g. they increase myocardial contractility, increase the flow of Ca.sup.2+ into the cell, increase blood pressure, reduce blood sugar, reduce swelling of mucous membranes and affect the salt and/or fluid balance.

Abstract: Novel ethers of organic compounds containing chiral atoms of the formula ##STR1## wherein A is a hydrocarbonated chain of 1 to 10 groups, the said chain containing one or more heteroatoms, one or more unsaturations, the assembly of the groups constituting the chain may represent a mono- or polycyclic system, including a system of the spiro or endo type, the chain A can contain one or more chiral atoms or the lactone moiety can present a chirality due to the dissymetric spatial configuration of the whole of the molecule and Z is selected from the group consisting of primary, secondary or tertiary alcohol moiety containing at least an asymetric carbon atom, a phenol moiety substituted comprising at least one asymetric carbon atom and a substituted alcohol or phenol moiety with a chirality due to the dissymetric spatial configuration of the whole of the molecule, with the proviso Z is not (R) or (S) .alpha.

Abstract: The present invention provides a novel 6-nitroprostaglandin derivatives of the formula (I) ##STR1## wherein A, n, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are as defined in claim 1.The 6-nitroprostaglandin derivatives is useful as medicines because of its excellent pharmacological activities including platelet aggregation inhibiting activity, blood pressure lowering activity and anti-ulcerous activity, and useful as intermediate for other pharmaceutically active compounds such as 6-oxoprostaglandin derivatives, prostaglandin E.sub.1 derivatives, etc.

Abstract: The optically active .gamma.-lactone of (1R, cis)-2, 2-dimethyl-3-hydroxymethyl-cyclopropane-1-carboxylic acid, which is useful as an intermediate in the production of pyrethroid insecticides, may be made from optically active (-)car-3-en-5-one by a two stage oxidation process followed by hydrolysis of the intermediate obtained.

Abstract: Novel 3-formyl-4-methyl-pent-3-ene-1-oic acid of the formula ##STR1## and a process for its preparation and intermediates and a process for the preparation of compounds of the formula ##STR2## wherein W is selected from the group consisting of hydrogen and R.sub.1 of an optionally chiral alcohol R.sub.1 OH, useful as an intermediate for the production of numerous esters having elevated insecticidal activity.